Mason RP, Jacob RF, Corbalan J, Malinski T. Combination treatment with eicosapentaenoic acid and atorvastatin active metabolite reverses endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract]. Presented at the Deuel Conference on Lipids, March 3-6, 2015, Monterey, California.

Mason RP, Jacob R, Corbalan JJ, Malinski T. Eicosapentaenoic acid reduces small dense low density lipoprotein oxidation and improves endothelial function in vitro as compared to other triglyceride-lowering agents [abstract]. J Am Coll Cardiol. 2015;65:A2139.

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR study). J Clin Lipidol. 2014 [Epub ahead of print].
Free:
http://www.lipidjournal.com/article/S1933-2874(14)00408-5/pdf

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects upon high-sensitivity C-reactive protein and lipid parameters in patients with metabolic syndrome. Metab Syndr Relat Disord. 2015 Apr 20 [Epub ahead of print].

Free:

http://online.liebertpub.com/doi/pdfplus/10.1089/met.2014.0137

Mason RP, Jacob RF. Eicosapentaenoic acid (EPA) reduces glucose-induced small dense low-density lipoprotein oxidation in vitro in a manner distinct from other triglyceride-lowering agents and vitamin E [abstract 705-P]. Diabetes. 2015;64(suppl 1):A178-A179. Posting of the abstract is pending permission by the Journal Diabetes.

Mason RP, Jacob RF. Eicosapentaenoic acid (EPA), but not other TG-lowering agents, reduces cholesterol domain levels in atherosclerotic-like model membranes [abstract 176]. J Clin Lipidol. 2015;9:466.

Ballantyne CM, Bays HE, Braeckman RA, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract 172]. J Clin Lipidol. 2015;9:463-4. 

Stirtan WG, Braeckman RA, Bays HE, Ballantyne CM, Soni PN, Juliano RA. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract 173]. J Clin Lipidol. 2015;9:464.